Association of CCR2-CCR5 Haplotypes and CCL3L1 Copy Number with Kawasaki Disease, Coronary Artery Lesions, and IVIG Responses in Japanese Children

Background The etiology of Kawasaki Disease (KD) is enigmatic, although an infectious cause is suspected. Polymorphisms in CC chemokine receptor 5 (CCR5) and/or its potent ligand CCL3L1 influence KD susceptibility in US, European and Korean populations. However, the influence of these variations on KD susceptibility, coronary artery lesions (CAL) and response to intravenous immunoglobulin (IVIG) in Japanese children, who have the highest incidence of KD, is unknown. Methodology/Principal Findings We used unconditional logistic regression analyses to determine the associations of the copy number of the CCL3L1 gene-containing duplication and CCR2-CCR5 haplotypes in 133 Japanese KD cases [33 with CAL and 25 with resistance to IVIG] and 312 Japanese controls without a history of KD. We observed that the deviation from the population average of four CCL3L1 copies (i.e., < or > four copies) was associated with an increased risk of KD and IVIG resistance (adjusted odds ratio (OR)  = 2.25, p = 0.004 and OR = 6.26, p = 0.089, respectively). Heterozygosity for the CCR5 HHF*2 haplotype was associated with a reduced risk of both IVIG resistance (OR = 0.21, p = 0.026) and CAL development (OR = 0.44, p = 0.071). Conclusions/Significance The CCL3L1-CCR5 axis may play an important role in KD pathogenesis. In addition to clinical and laboratory parameters, genetic markers may also predict risk of CAL and resistance to IVIG.

[1]  Kei Takahashi,et al.  Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[2]  E. Silverman,et al.  Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. , 1997, The Journal of rheumatology.

[3]  B. Rovin,et al.  The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .

[4]  M. Hammer,et al.  Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Newburger,et al.  Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. , 1998, The Pediatric infectious disease journal.

[6]  S. Colan,et al.  Coronary artery dimensions may be misclassified as normal in Kawasaki disease. , 1998, The Journal of pediatrics.

[7]  Jane C Burns,et al.  Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. , 2005, The Journal of infectious diseases.

[8]  A. J. Valente,et al.  Evolution of Human and Non-human Primate CC Chemokine Receptor 5 Gene and mRNA , 2000, The Journal of Biological Chemistry.

[9]  T. Matsuishi,et al.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. , 2006, The Journal of pediatrics.

[10]  T. Onodera,et al.  Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. , 2000, The Journal of pediatrics.

[11]  K. Matsushima,et al.  Dramatic decrease of circulating levels of monocyte chemoattractant protein‐1 in Kawasaki disease after gamma globulin treatment , 1999, Journal of leukocyte biology.

[12]  K. Yamada,et al.  Coronary risk factors in Kawasaki disease treated with additional gammaglobulin , 2004, Archives of Disease in Childhood.

[13]  S. Kurotobi,et al.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment , 2006, European Journal of Pediatrics.

[14]  Yusuke Nakamura,et al.  Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. , 2008, American journal of human genetics.

[15]  Kejun Liu,et al.  PowerMarker: an integrated analysis environment for genetic marker analysis , 2005, Bioinform..

[16]  A. Morikawa,et al.  [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease]. , 2008, Nihon rinsho. Japanese journal of clinical medicine.

[17]  B. Neel,et al.  FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. , 2007, Immunity.

[18]  Naoko Kinukawa,et al.  Association of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Gene Polymorphisms with Coronary Artery Lesions of Kawasaki Disease , 2004, Pediatric Research.

[19]  J. Van Damme,et al.  Macrophage inflammatory protein-1. , 2002, Cytokine & growth factor reviews.

[20]  Yu-Lung Lau,et al.  Inflammatory Gene Polymorphisms and Susceptibility to Kawasaki Disease and Its Arterial Sequelae , 2008, Pediatrics.

[21]  S. Kikuchi,et al.  C–C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis , 2003, Journal of Neuroimmunology.

[22]  Jong-Keuk Lee,et al.  The CCR5 (−2135C/T) Polymorphism may be Associated with the Development of Kawasaki Disease in Korean Children , 2008, Journal of Clinical Immunology.

[23]  Chan-Wook Woo,et al.  Predictive risk factors for coronary artery abnormalities in Kawasaki disease , 2007, European Journal of Pediatrics.

[24]  Tomio Kobayashi,et al.  Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients With Kawasaki Disease , 2006, Circulation.

[25]  M. Ballow Clinical and investigational considerations for the use of IGIV therapy. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[26]  B. Rovin,et al.  CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus , 2007, Annals of the rheumatic diseases.

[27]  M. Baggiolini,et al.  CCR5 is characteristic of Th1 lymphocytes , 1998, Nature.

[28]  P. Fietta,et al.  The effector T helper cell triade. , 2009, Rivista di biologia.

[29]  J. Guzman-Cottrill,et al.  Recent developments and controversies in Kawasaki disease. , 2004, Minerva pediatrica.

[30]  J. Newburger,et al.  Resistance to intravenous immunoglobulin in children with Kawasaki disease. , 2008, The Journal of pediatrics.

[31]  Y. Kawakami,et al.  The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. , 1999, American journal of respiratory and critical care medicine.

[32]  M. Adams,et al.  Recent Segmental Duplications in the Human Genome , 2002, Science.

[33]  T Enright,et al.  Kawasaki syndrome. , 1990, Annals of allergy.

[34]  T. Ueland,et al.  Chemokines and Cardiovascular Risk , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[35]  P. O’Connell,et al.  Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression , 1998, Nature Medicine.

[36]  R. Sittiwangkul,et al.  Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. , 2006, Singapore medical journal.

[37]  A. Billiau,et al.  How interferon-gamma keeps autoimmune diseases in check. , 2008, Trends in immunology.

[38]  L. Jonides,et al.  Kawasaki disease. , 1994, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[39]  R. Welch,et al.  Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease , 2007, Clinical and experimental immunology.

[40]  Y. Kohno,et al.  Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. , 2001, Arthritis and rheumatism.

[41]  T. Asano,et al.  Expression of IL‐8 in Kawasaki disease , 2000, Clinical and experimental immunology.

[42]  D. Conrad,et al.  Global variation in copy number in the human genome , 2006, Nature.

[43]  Yusuke Nakamura,et al.  ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms , 2008, Nature Genetics.

[44]  L. Barcellos,et al.  Gene copy number regulates the production of the human chemokine CCL3‐L1 , 2002, European journal of immunology.

[45]  M. Hara,et al.  A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. , 2003, The Journal of pediatrics.

[46]  R. Cantor,et al.  Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease , 2005, Genes and Immunity.

[47]  Ogawa,et al.  Expression of Monocyte Chemoattractant Protein‐1 in Kawasaki Disease: The Anti‐Inflammatory Effect of Gamma Globulin Therapy , 2000, Scandinavian Journal of Immunology.

[48]  J. Ottenkamp,et al.  The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease , 2006, Clinical and experimental immunology.

[49]  S. Shulman,et al.  New developments in the search for the etiologic agent of Kawasaki disease , 2007, Current opinion in pediatrics.

[50]  B. Neel,et al.  FcγRIII-Dependent Inhibition of Interferon-γ Responses Mediates Suppressive Effects of Intravenous Immune Globulin , 2007 .

[51]  Paul D. Mitchell,et al.  Coronary Artery Involvement in Children With Kawasaki Disease: Risk Factors From Analysis of Serial Normalized Measurements , 2007, Circulation.

[52]  L. Benson,et al.  Outcome of coronary artery aneurysms after Kawasaki disease. , 1992, The Journal of pediatrics.

[53]  Yoshikazu Nakamura,et al.  Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition) , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[54]  Norishige Yoshikawa,et al.  A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. , 2005, The Journal of pediatrics.

[55]  Lei Wan,et al.  Influence of interleukin 18 promoter polymorphisms in susceptibility to Kawasaki disease in Taiwan. , 2008, The Journal of rheumatology.

[56]  J. Anaya,et al.  Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases , 2010, Genes and Immunity.

[57]  K. Yoon,et al.  Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease , 2008, Journal of Korean medical science.